Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Patients with triple-class-exposed relapsed and refractory multiple myeloma have a dismal prognosis. B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) has previously produced profound, long-lasting responses in individuals with multiple myeloma that has relapsed or become resistant to treatment.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form